Last €16.94 EUR
Change Today +0.02 / 0.12%
Volume 78.9K
AB On Other Exchanges
EN Paris
As of 11:35 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/10/15 - €18.93
52 Week Low
10/16/14 - €7.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

112 Employees
Last Reported Date: 08/29/14
Founded in 2001

ab science sa (AB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €456.7K
Compensation as of Fiscal Year 2013.

ab science sa (AB) Key Developments

AB Science SA Completes Futility Analysis Related to the masitinib Phase 3 Trial for the Treatment of Mild to Moderate Alzheimer's Disease

AB Science SA announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended the continuation of the study. Phase 3 status: The ongoing phase 3 trial is a double-blind, randomized, placebo-controlled study (AB09004) designed to assess the safety and efficacy of masitinib in patients with confirmed mild to moderate Alzheimer's disease. The treatment period is 24 weeks and masitinib is being given as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine and/or memantine). The main measures are the change in two commonly used clinical assessments: the effect on ADCS-ADL, which measures self-care and activities of daily living assessed, and the effect on ADAS-Cog, which measures the effect on cognition and memory. The study is intended to enroll about 600 patients. The study was recently assessed as non-futile by the IDMC. A futility analysis tests the inability of a clinical study to achieve its efficacy objective. Therefore, a conclusion that a study is not futile suggests that a clinical study has the potential to achieve its stated efficacy objective. The IDMC analysis was performed after about one third of the patients were enrolled into the study and had reached the 24 week treatment duration period. The study previously successfully passed all safety data reviews by the IDMC, indicating that there is no major or unexpected safety concern with masitinib in this patient population.

AB Science Announces Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer

AB Science SA announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment. This was a prospective, multicenter, open-label, randomized, uncontrolled, phase 1b/2 study to evaluate efficacy and safety of masitinib in association with chemotherapy for the treatment of recurrent gastric or gastro-esophageal junction adenocarcinoma. Patients received masitinib in combination with irinotecan, or FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), or 5-fluorouracil, after progression to platinum-based first-line chemotherapy. In the masitinib plus irinotecan treatment-arm, median overall survival (OS) and progression-free survival (PFS) were 13.4 and 3.9 months, respectively. Safety data showed that the combination of masitinib and irinotecan had an acceptable safety profile. In the masitinib plus FOLFIRI treatment-arm, median OS and PFS were 10.9 and 2.4 months, respectively. Again, safety data showed that the combination of masitinib and FOLFIRI had an acceptable safety profile. The masitinib plus 5-fluorouracil treatment-arm was closed early due to lack of efficacy on PFS.

AB Science S.A. to Report Q4, 2014 Sales/Trading Statement Results on Feb 27, 2015

AB Science S.A. announced that they will report Q4, 2014 sales/trading statement results on Feb 27, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €16.94 EUR +0.02

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies

Industry Analysis


Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 232.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 211.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at